I have been at American Association of Clinical Oncologists (ASCO) since last Thursday. On the prostate cancer front the most exciting part of the meeting has been our being in Chicago and that the weather which has been fantastic. The only truly newsworthy thing that I have come across so far has been an abstract [...]
Men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) will eventually develop debilitating pain that impacts daily functioning and diminishes their quality of life. Based on prior studies, including a phase III trial, the superiority of denosumab over zoledronic acid (ZA) in delaying or preventing skeletal-related events (pathological fracture, radiation or surgery to the [...]
As usual, we are confronted with a new contradiction. It has been believed that earl hormone therapy (ADT) in men with a biochemical recurrence (PSA only) would benefit from immediate ADT. A study released from the Harvard School of Public Health contradicts this assumption, but the study lacks follow up beyond 10 years. They evaluated [...]
Given all the newly approved drugs available to us to treat advanced prostate cancer there now are many questions about the optimal sequencing of these drugs and whether earlier use of one causes cross-resistance to another. Recently, it was reported that chemotherapy with docetaxel is inactive in men with metastatic castrate resistant prostate cancer (mCRPC) [...]
In our quest to understand our prostate cancer we have developed many “measures” of our disease aggressiveness and progression. Many of these measures are generally accepted has valid, but many have never been validated. One example is the prognostic nature of PSA Doubling Time (PSADT) in men with biochemically recurrent prostate cancer (BRPC or PSA [...]
One of the more recent conversations surrounding prostate cancer treatment that we have been hearing involves the use of the anti-cholesterol drugs or statins. The conversation, whether or not statins might be a good treatment option for men with both localized disease and as an alternative to hormone treatment (ADT) for men with advanced prostate [...]
It has always been assumed that Ketoconazole, when used for the treatment of men with metastatic castration resistant prostate cancer (mCRPC), would not be as potent as abiraterone (Zytiga), but there has never been any head to head comparison to demonstrate this assumption! Ketoconazole is a less potent inhibitor of the CYP-17 enzyme, the mode [...]
It is a widely understood that androgen deprivation therapy (ADT) causes adverse side effects and events. Some researchers believe that the ADT-induced alterations in lipid and glucose metabolism may be race-dependent. To evaluate this concern the researchers recruited Japanese men with newly diagnosed prostate cancer who also underwent at least one year of ADT. They [...]
We all are subject to developing depression and prostate cancer survivors are subject to a large share of it. Besides dealing with the everyday issues of living our life, we also are hounded by our diagnosis. However, it is important to understand that there are everyday types of depression and what is referred to as [...]
Men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) will often have debilitating pain that impacts every aspect of their daily functioning thus significantly diminishing their quality of life (QoL). Finding the best drug or treatment to control the pain will allow men to have a more complete and fulfilling life as well as [...]
